Nasdaq:GEHC
GE HealthCare Technologies Inc.
A global medical technology giant delivering advanced imaging and monitoring solutions that are reshaping hospital workflows and patient outcomes.
Key Metrics
Investment Thesis
Bull Case
Investors should consider GEHC a compelling value play given its strong balance sheet with $4.49B in cash against manageable long-term debt of $9.49B, providing ample flexibility for M&A and capital returns. The company's transition toward high-margin software and service revenue offers durable growth visibility beyond the cyclical hardware sales cycle typical of medical device firms. A valuation below historical averages combined with consistent free cash flow conversion suggests a significant margin of safety for long-term holders.
Bear Case
Potential downside risks include the lingering impact of aggressive pricing concessions that may suppress gross margins and limit total shareholder returns in the near term. Heavy investment in R&D of $1.26B and acquisitions creates near-term earnings pressure that could delay a return to peak profitability levels seen in prior years. Geopolitical tensions and supply chain disruptions in key component markets could further impact production capabilities and delivery timelines for critical imaging equipment.
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global leader in medical imaging, patient monitoring, and digital health solutions serving hospitals, clinics, and home care markets worldwide. The company leverages its extensive portfolio of MRI, CT, ultrasound, and X-ray systems alongside AI-driven software platforms to transform healthcare delivery. With strong cash generation and a diversified product mix, GEHC balances high-growth digital initiatives with robust hardware sales across developed and emerging economies.
Analysis
Management Discussion
Management delivered solid operational performance in 2025 with revenue growing to $20.62B and net profit reaching $2.15B, reflecting a resilient business model despite challenging market conditions. The cash flow from operations of $1.99B significantly outpaced the $2.15B net income, indicating strong quality of earnings and efficient working capital management with minimal inventory buildup compared to prior periods. Strategic acquisitions totaling $378M suggest continued investment in digital capabilities and service expansion to capture recurring revenue streams.
Industry Overview
The global medical technology industry is undergoing a digital transformation where hardware sales are increasingly complemented by subscription-based software services and remote patient monitoring solutions. Consolidation among large players like GEHC, Siemens Healthineers, and Philips has intensified competition, yet the aging healthcare infrastructure in many nations continues to drive replacement demand for imaging equipment. Regulatory environments worldwide are tightening around pricing transparency and value-based purchasing, reshaping how companies structure their contracts and revenue recognition.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $19.55B | $19.67B | $20.62B |
| Cost of Revenue | $11.63B | $11.47B | $12.38B |
| Gross Profit | $7.92B | $8.21B | $8.25B |
| Operating Expenses | $5.49B | $5.58B | $5.49B |
| Operating Income | $2.44B | $2.62B | $2.76B |
| R&D | $1.21B | $1.31B | $1.26B |
| G&A | $4.28B | $4.27B | $4.22B |
| Stock-Based Comp | $114.0M | $125.0M | $130.0M |
| Depreciation | $248.0M | $268.0M | $287.0M |
| Amortization | $362.0M | $312.0M | $291.0M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-74.0M | $-44.0M | $5.0M |
| Pre-Tax Income | $2.36B | $2.58B | $2.77B |
| Income Tax | $743.0M | $531.0M | $614.0M |
| Continuing Ops | $1.62B | $2.05B | $2.15B |
| Discontinued Ops | $-4.0M | $0 | $0 |
| Net Income | $1.61B | $2.05B | $2.15B |
| Minority Interest | $46.0M | $57.0M | $70.0M |
| Net to Common | $1.57B | $1.99B | $2.08B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $9.41B | $9.90B | $12.50B |
| Cash & Equivalents | $2.49B | $2.87B | $4.49B |
| Inventory | $1.96B | $1.94B | $2.23B |
| Other Current Assets | $4.96B | $5.09B | $5.78B |
| Long-Term Assets | $23.04B | $23.19B | $24.41B |
| PP&E (Net) | $2.14B | — | — |
| Intangibles | $1.25B | $1.08B | $1.13B |
| Goodwill | $12.94B | $13.14B | $13.49B |
| Operating Leases | $356.0M | $364.0M | $410.0M |
| LT Investments | $357.0M | $373.0M | $351.0M |
| Other LT Assets | $5.83B | $8.07B | $9.00B |
| Total Assets | $32.45B | $33.09B | $36.91B |
| Current Liabilities | $8.98B | $9.55B | $9.11B |
| Accounts Payable | $2.95B | $3.02B | $3.25B |
| Current Debt | — | $1.50B | $502.0M |
| Current Leases | $110.0M | $115.0M | $134.0M |
| Deferred Revenue | $1.92B | $1.94B | $2.10B |
| Other Current Liab | $4.01B | $2.97B | $3.12B |
| Long-Term Liabilities | $16.16B | $14.88B | $17.20B |
| Long-Term Debt | $8.44B | $7.45B | $9.49B |
| LT Operating Leases | $273.0M | $270.0M | $284.0M |
| Other LT Liab | $6.75B | $6.48B | $6.62B |
| Total Liabilities | $25.14B | $24.44B | $26.31B |
| Shareholders' Equity | $7.31B | $8.65B | $10.60B |
| Paid-In Capital | $6.49B | $6.58B | $6.71B |
| Retained Earnings | $1.33B | $3.26B | $5.28B |
| AOCI | $-691.0M | $-1.38B | $-1.39B |
| Total L&E | $32.45B | $33.09B | $36.91B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.61B | $2.05B | $2.15B |
| Non-Cash Adjustments | $488.0M | $-505.0M | $-790.0M |
| Working Capital Changes | $-1.0M | $406.0M | $623.0M |
| Cash from Operations | $2.10B | $1.95B | $1.99B |
| Cash from Investing | $-558.0M | $-914.0M | $-1.05B |
| Share Buybacks | — | — | $200.0M |
| Dividends Paid | $41.0M | $55.0M | $64.0M |
| Cash from Financing | $-478.0M | $-573.0M | $617.0M |
| FX Effect | $-10.0M | $-77.0M | $66.0M |
| Net Change in Cash | $1.05B | $387.0M | $1.62B |
| Beginning Cash | $1.45B | $2.51B | $2.89B |
| Ending Cash | $2.51B | $2.89B | $4.51B |
Frequently Asked Questions
How does GE HealthCare Technologies Inc. make money?
The company's revenue is driven by four primary segments: Imaging Systems (MRI, CT, Ultrasound), Patient Monitoring (ICU, OR, and ambulatory care devices), Digital Health & AI software platforms, and Service & Supply Chain operations providing maintenance, leasing, and consumables.
What are the main risks for GEHC?
Regulatory headwinds from the U.S. Inflation Reduction Act and other jurisdictions threaten to erode margins through forced price concessions on imaging equipment. The company faces significant competition from lower-cost Asian manufacturers who are gaining share in developing markets, potentially pressuring pricing power on standard diagnostic equipment. High exposure to macroeconomic cycles affects discretionary capital spending by healthcare systems on expensive imaging upgrades and infrastructure projects.
What is GEHC's competitive advantage?
GEHC possesses a dominant market share in high-end MRI technology with deep moats built on proprietary physics engines and long-term service contracts that ensure recurring revenue streams. Its integrated digital ecosystem connects hardware devices with cloud-based analytics, creating high switching costs for healthcare providers and enabling data-driven clinical insights. A diversified global footprint across over 130 countries provides resilience against regional economic downturns while capturing growth in emerging markets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.